Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Canon loses court challenge against EU fine over 2016 acquisition

Published 05/18/2022, 05:38 AM
Updated 05/18/2022, 06:06 AM
© Reuters. People are silhouetted against a display of the Canon brand logo at the CP+ camera and photo trade fair in Yokohama, Japan, February 25, 2016. REUTERS/Thomas Peter/Fies

By Foo Yun Chee

BRUSSELS (Reuters) -Japanese camera and printer maker Canon lost its challenge against a 28 million euros ($29.4 million) EU fine on Wednesday after Europe's second-top court upheld the sanction imposed for jumping the gun in a 2016 acquisition.

Companies which close a deal without first securing EU regulatory approval or provide misleading information during the regulatory review can face fines up to 10% of their aggregated turnover under EU merger rules.

The European Commission in its 2019 decision said Canon breached the rules by using a so-called "warehousing" two-step transaction structure involving an interim buyer to purchase Toshiba (OTC:TOSYY) Corp's medical unit before gaining regulatory clearance.

The unorthodox method allowed Toshiba, which was struggling for cash after an accounting scandal, to book proceeds in time for the financial year-end ending in March.

The Luxembourg-based General Court backed the EU competition enforcer's finding.

"The (European) Commission was therefore right to observe that the Court's case-law distinguishes between the concepts of 'concentration' and 'implementation of a concentration'," judges said.

In a recent gun-jumping case, the EU competition watchdog ordered U.S. life science company Illumina (NASDAQ:ILMN)'s to keep cancer detection test maker Grail Inc as a separate company after the former completed the deal while still waiting for the regulatory green light. The case is still pending.

The Commission has in recent years handed out stiff fines to Meta, General Electric (NYSE:GE) and German drugmaker Merck KGaA for giving misleading information during reviews of their deals.

The case is T-609/19 Canon V Commission.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

($1 = 0.9515 euros)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.